Track topics on Twitter Track topics that are important to you
“I am pleased to report that Midatech's US commercial business has continued to grow strongly in 2017"
The candidate is based on Midatech's gold nanoparticle technology that targets tumour cells more precisely
Midatech Pharma Inc (LON:MTPH) can look towards 118p if it can break through the 50-day moving average suggests technical analyst Zak Mir.
Dosing has begun using Midatech’s MTX110 in patients with diffuse intrinsic pontine glioma (DIPG), a highly aggressive strain of the disease
Midatech Pharma Plc (LON:MTPH, NASDAQMTP) boss tells us how the company has secured a US$15mln, four-year senior loan facility that will be used to bankroll the clinical development of two promising...
In this exclusive interview, Fintan Walton talks to Tom Rademacher, President of Midatech, about the formation of the biotech, Professor Rademacher's fifth start-up company. Tom discusses Midatech's b...
Midatech wants to demonstrate that Q-Octreotide can achieve safe and effective growth hormone levels while also highlighting the advantages of its release system
Midatech has three lead R&D programmes: a carcinoid syndrome treatment; a liver cancer drug; and a brain cancer therapy
Midatech Ltd, UK, is a world leader in the design, synthesis and manufacture of biocompatible nanoparticles. These nanoparticles can be used to create a wide variety of products w...
Midatech Ltd, UK, is a world leader in the design, synthesis and manufacture of biocompatible nanoparticles. These nanoparticles can be used to create a wide variety of products with novel character...
We have published hundreds of Midatech Ltd. news stories on BioPortfolio along with dozens of Midatech Ltd. Clinical Trials and PubMed Articles about Midatech Ltd. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Midatech Ltd. Companies in our database. You can also find out about relevant Midatech Ltd. Drugs and Medications on this site too.